Moises Zanetti, Author at JCR Pharmaceuticals

FY2025 second quarter results briefing session material

by Moises Zanetti

FY2025 second quarter results briefing session - movie

by Moises Zanetti

FY2025 Second quarter results briefing session material

by Moises Zanetti

FY2025-Q2 Financial report (Jul. 1-Sep. 30, 2025)

by Moises Zanetti

JCR Pharmaceuticals enhances delivery of AAV gene therapy to central nervous system and muscle with novel capsid engineering platform technology

by Moises Zanetti

JCR Pharmaceuticals announces licensing agreement with Menagen to commercialize Agalsidase Beta BS I.V. Infusion [JCR] across nine MENAT markets

by Moises Zanetti

Corporate governance report

by Moises Zanetti

JCR Pharmaceuticals to present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

by Moises Zanetti

Notice of orphan drug designation for JR-446 for mucopolysaccharidosis type IIIB by Ministry of Health, Labour and Welfare of Japan

by Moises Zanetti

JCR Pharmaceuticals unveils new corporate tagline, “Life is Rare,” to mark its 50th anniversary

by Moises Zanetti